南新制药拟收购未来医药持有的标的资产组

Core Viewpoint - Nanjing Pharmaceutical plans to acquire a set of assets from Future Medicine for a total consideration of up to 480 million yuan, which includes both listed and in-development products related to multi-trace element injection solutions, enhancing its product pipeline and aligning with its health management strategy [1] Group 1: Acquisition Details - The acquisition involves cash payment for assets including "Multi-trace Element Injection (I)", "Multi-trace Element Injection (II)", and the in-development "Multi-trace Element Injection (III)" [1] - The transaction is expected to constitute a significant asset restructuring as defined by the regulations for listed companies [1] - The overall valuation for the transaction is projected to be no more than 480 million yuan [1] Group 2: Strategic Implications - This acquisition will enrich the company's product pipeline and improve its product matrix for "whole-age health management" [1] - It aims to optimize the company's layout in the "anti-infection - chronic disease - nutritional support" sectors [1] - The move aligns with the company's broader "big health" development strategy [1]